Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The Reimbursement Math Has Already Changed
Operators who still build SUD pro formas around residential admissions are pricing a contracting environment that has already moved on. Commercial payers and federal agencies are paying for longitudinal engagement, medication continuation, and post-discharge retention, not repeat 28-day stays.
Last quarter I worked with a 60-bed Level 3.5 residential program in the Southeast. Strong census, decent margins, single-state footprint. The payer mix was telling the founder something he did not want to hear. Two of his three largest commercial contracts had tightened concurrent review on residential days, and one was offering enhanced rates for outpatient bundles that included MAT induction, care coordination, and 90-day post-discharge engagement. The residential admission was no longer the prize. The continuum was.
The clinical evidence backs the payers. NIDA has been clear for years that SUD should be treated like any other chronic illness, with relapse rates of 40 to 60 percent, comparable to hypertension and asthma. CDC’s MMWR reported 81,806 opioid-involved overdose deaths in 2022, and only 25.1 percent of adults who needed OUD treatment received medications for OUD. That gap is the payer’s business case. They are buying medication continuation and engagement because the alternative is overdose and readmission.
The ASAM Criteria, 4th Edition reflects this. ASAM frames treatment as a continuum, with patients reassessed and moved across levels of care based on the dimensional admission criteria, not parked at a single product. The 4th Edition even added a new Level 1.0 Long-Term Remission Monitoring designation. If your clinical model and your pro forma still treat detox and residential as the revenue engine, you are building toward a contracting environment that is already receding.
What a Chronic-Care Model Actually Looks Like Operationally
Reframing SUD as a chronic disease changes what you build, who you hire, and how you bill. A real longitudinal model integrates MAT (buprenorphine, naltrexone, methadone where licensed), primary care touchpoints, behavioral health therapy, and care coordination across at least 12 months post-acute. The clinical justification is not theoretical. Methadone is associated with a decrease in all-cause mortality of more than 50 percent, and SAMHSA describes MAT as combining medications and behavioral therapies for a whole-patient approach.
Patients move from medically managed residential settings down through Level 2.5 partial hospitalization (which is outpatient), Level 2.1 IOP, Level 1 outpatient, and into recovery management. The handoffs are documented, warm, and measurable. ASAM’s own framing is direct: “As a patient moves through treatment, they are regularly reassessed” to determine the next level of care.
Operationally that means a few things most operators are not set up for:
- Shared EMR instances across levels of care so a patient’s record actually follows them.
- Care coordinators with defined caseloads and documented contact cadence.
- MAT prescribers credentialed across your service lines, not just at the residential site.
- Outcome data captured at intake, discharge, 30, 90, and 180 days.
- Co-occurring enhanced capability built into the standard of care, not bolted on, since the 4th Edition incorporates co-occurring capable standards into the core requirements for every level of care.
Without those pieces, you cannot tell a payer a credible story about longitudinal value, and you cannot bill for the codes that are starting to matter.
Feasibility Studies and Pro Formas: Stop Modeling One-Time Admissions
When AHS runs a feasibility study for a buyer or a CEO considering expansion, the first thing we look at is whether the existing pro forma assumes recurring revenue or one-time admissions. Most do the latter. They model average length of stay, average daily rate, and a churn assumption. That math works in a stable residential market. It does not work when your largest payer wants to contract for a 12-month episode of care with quality bonuses tied to retention and MAT continuation.
A longitudinal pro forma looks different. Operators who build it correctly model patient-months rather than admissions. They assume a smaller residential footprint feeding a larger outpatient and IOP footprint, with care coordination and MAT management generating recurring touchpoints. They account for the staffing ratios required to actually deliver Level 2.5 PHP and Level 2.1 IOP at the weekly hour minimums payers will hold them to in utilization review. And they stress-test what happens when commercial payers shift 20 percent of their authorized days from residential to outpatient.
If your model breaks under that scenario, you do not have a model. You have a bet. The clinical data justifying the shift is not soft. Researchers analyzing nearly 92 million patient records in the US Collaborative Network found that buprenorphine-naloxone is associated with reduced mortality and increased remission in OUD patients. Payers read the same studies operators do. They are pricing the continuum because the continuum is what works.
Licensure and Build/Buy Decisions for Completing the Continuum
If you are residential-only today and you want to be defensible in five years, you have a build-or-buy decision in front of you. Licensure pathways for outpatient, IOP, PHP, and care coordination vary dramatically by state.
In Florida, DCF licenses substance use disorder providers under Chapter 397, Florida Statutes, and Chapter 65D-30, Florida Administrative Code, with separate program components for detox, residential, PHP, and IOP. Florida’s regulators have moved aggressively in recent sessions, with CS/HB 295 directing DCF to establish fines for failed inspections and improper referrals. In Colorado, HCPF has issued formal guidance aligning the state’s behavioral health benefit with the ASAM Criteria 4th Edition, which changes how providers document medical necessity and request authorization. In Illinois, IDHS/SUPR has published a formal transition plan from the 3rd to the 4th Edition under Administrative Code Part 2060. None of this is insurmountable. None of it is a 60-day project either.
For PE-backed buyers, the more common move is acquisition of an existing outpatient platform and integration into a residential portfolio. That works only if the diligence covers the things that actually break post-close: payer contracts that do not transfer cleanly, EMR systems that cannot share records, utilization review processes that are not aligned across sites, and documentation standards that do not match across legacy and acquired entities. We have seen deals close on strong financials and then lose 18 months unwinding compliance gaps that should have been priced into the LOI.
What CEOs Should Do in the Next 90 Days
Three concrete moves.
- Pull your authorization data. Look at the last 12 months of authorization data and the trend line on residential days approved versus outpatient days approved by your top five payers. If residential is flat or declining and outpatient is growing, your strategy needs to follow the money.
- Commission a longitudinal feasibility study. Model your existing book under a longitudinal reimbursement assumption, not an admissions assumption. If you do not like what you see, you have time to fix it.
- Audit your continuum for handoff points. Where do patients fall out between Level 3.5 and Level 2.5? Between IOP and outpatient? Those gaps are where outcomes die and where payers are watching. ASAM’s free Level of Care Assessment Guide, pilot tested by UCLA’s Integrated Substance Use and Addiction Programs, is a reasonable starting point for standardizing those transition decisions.
Shalini Karapetian and I will both be at WCSAD 2026 in late May, and AHS is sponsoring the South Florida Behavioral Health Coffee Morning at Harvest Patio in Boca Raton on May 20th. If you are working through a feasibility study, a continuum build-out, or pre-acquisition diligence, find us at either event. These conversations go better in person than over email.
Frequently asked questions
Is SUD really a chronic disease, or is that just a payer talking point?
Both. NIDA explicitly states that substance use disorders should be treated like any other chronic illness, citing relapse rates of 40 to 60 percent that are comparable to hypertension and asthma (NIDA, Drugs, Brains, and Behavior). SAMHSA frames recovery as a long-term process of change, and the DSM-5 classifies SUDs as chronic, relapsing conditions. Payers are using that clinical consensus to justify longitudinal contracts and quality bonuses tied to retention and MAT continuation.
What does the ASAM Criteria 4th Edition change for operators?
The 4th Edition, published in 2023, keeps the four broad treatment levels but updates the dimensions, integrates co-occurring capable standards into every level of care, adds a new Level 1.0 Long-Term Remission Monitoring, and introduces a Level 3.7 BIO designation for programs with enhanced biomedical capabilities (ASAM and Colorado HCPF summary documents). For operators that means redocumenting medical necessity, retraining clinicians, updating EMR templates, and confirming each state Medicaid agency’s adoption timeline before assuming your old utilization review playbook still works.
How does MAT actually move outcomes in a longitudinal model?
MAT with methadone is associated with a decrease in all-cause mortality of more than 50 percent (American Family Physician, citing the SAMHSA Treatment Improvement Protocol literature). A 2024 retrospective study in the Western Journal of Emergency Medicine analyzing nearly 92 million patient records found that buprenorphine-naloxone reduced mortality and increased remission in OUD patients. Yet per CDC’s 2024 MMWR, only 25.1 percent of US adults who needed OUD treatment in 2022 received medications for OUD. That gap is the clinical, ethical, and financial argument for building MAT capacity across every level of care, not just at the residential site.
If I am residential-only in Florida today, what is the fastest path to a defensible continuum?
Florida DCF licenses each SUD service component separately under Chapter 397, F.S. And Rule 65D-30, F.A.C. (myflfamilies.com). Recent legislation, including CS/CS/CS/HB 1065, authorizes DCF to consolidate components onto a single license for the same provider, which can simplify multi-site continuum operations. The fastest defensible path is usually a hybrid: file for the outpatient/IOP/PHP components you can stand up internally on your existing operational backbone, and acquire an established outpatient platform for the geographies where you need scale immediately. Either way, diligence on payer contracts, EMR interoperability, and utilization review documentation has to be done before the LOI, not after.
References
- American Society of Addiction Medicine. The ASAM Criteria, 4th Edition
- National Institute on Drug Abuse. Treatment and Recovery (Drugs, Brains, and Behavior: The Science of Addiction)
- CDC MMWR. Treatment for Opioid Use Disorder: Population Estimates, United States, 2022
- SAMHSA. Substance Use Disorder Treatment
- Florida DCF. Substance Use Disorder Licensing and Regulation (Chapter 397 F.S. / 65D-30 F.A.C.)
- Colorado HCPF. The ASAM Criteria Fourth Edition Summary
- Illinois DHS/SUPR. Transition from ASAM 3rd to 4th Edition
- American Family Physician. Opioid Use Disorder: Medical Treatment Options
- Western Journal of Emergency Medicine. Buprenorphine-Naloxone for OUD: Reduction in Mortality and Increased Remission (2024)